Leap Therapeutics, Inc. (LPTX)

Leap Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	65	106	45	286	134	27
Market Cap Growth	68.66%	137.81%	-84.43%	113.18%	395.35%	-7.85%
Enterprise Value	9	34	-22	171	81	23
PE Ratio	-	-1.30	-0.82	-7.05	-3.57	-0.81
PS Ratio	-	-	-	190.77	89.49	-
PB Ratio	1.37	1.76	0.76	2.65	2.88	-15.49
P/FCF Ratio	-1.46	-2.42	-0.91	-8.14	-5.18	-1.00
P/OCF Ratio	-1.46	-2.42	-0.91	-8.14	-5.17	-1.01
EV/Sales Ratio	-	-	-	113.99	54.22	-
EV/EBITDA Ratio	-0.23	-0.42	0.40	-4.22	-2.96	-0.69
EV/EBIT Ratio	-0.23	-0.42	0.40	-4.21	-2.96	-0.69
EV/FCF Ratio	-0.27	-0.79	0.44	-4.86	-3.14	-0.84
Debt / Equity Ratio	0.00	-	0.00	0.00	0.00	-0.32
Debt / EBITDA Ratio	0.00	-	0.00	0.00	-0.01	-0.02
Debt / FCF Ratio	0.00	-	-0.01	0.00	-0.01	-0.02
Quick Ratio	5.44	5.71	6.12	11.65	7.21	0.61
Current Ratio	5.38	5.65	6.05	11.70	7.09	0.50
Asset Turnover	0	0	0	0.02	0.03	0
Interest Coverage	-	-	-1007.31	-989.51	-704.54	-1429.57
Return on Equity (ROE)	-81.00%	-133.20%	-70.30%	-55.40%	-84.70%	-418.10%
Return on Assets (ROA)	-68.90%	-90.90%	-61.90%	-49.20%	-71.10%	-196.20%
Return on Capital (ROIC)	-124.44%	-144.73%	-96.00%	-38.38%	-60.99%	2794.57%
Earnings Yield	-82.53%	-76.83%	-122.52%	-14.18%	-28.00%	-122.73%
FCF Yield	-72.01%	-41.29%	-110.06%	-12.29%	-19.32%	-99.59%
Buyback Yield / Dilution	-108.85%	-80.55%	-31.94%	-44.66%	-162.71%	-56.69%
Total Shareholder Return	-108.85%	-80.55%	-31.94%	-44.66%	-162.71%	-56.69%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).